Campbell Shannon 4

What Happened Shannon Campbell, a director of Black Diamond Therapeutics (BDTX), was granted a derivative award covering 40,000 shares on June 26, 2026. The Form 4 reports acquisition at $0.00 per share (total reported value $0), i.e., an equity-based award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-26; Filing date: 2026-06-29 (filed within the Form 4 reporting window).
• Transaction type: Award/grant of derivative securities (Form 4 code A).
• Amount: 40,000 shares; reported price: $0.00; reported total value: $0.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: The award vests in full on the earlier of (i) June 26, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to Campbell’s continued service.

Context This is a grant of equity-based compensation (derivative securities) to a director, not an immediate purchase or sale of stock. The $0.00 reporting indicates no cash was paid at grant; the award will convert to vested equity only if vesting conditions are met. The filing appears timely (filed within the required reporting window).